<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00954005</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT00954005</nct_id>
  </id_info>
  <brief_title>Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma</brief_title>
  <acronym>R-GO</acronym>
  <official_title>Multicentric Phase I/II Study for the Efficacy of a Combination of Rituximab, Gemcitabine and Oxaliplatin in Relapsed/Refractory Indolent Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Low Grade Lymphoma Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Low Grade Lymphoma Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the phase I part is to determine the tolerability, the initial safety profile
      and maximum tolerated dose of oxaliplatin in combination with gemcitabine for indolent
      lymphoma. In the phase II part the investigators want to estimate the activity of gemcitabine
      and oxaliplatin in combination with rituximab for patients with relapsed/refractory indolent
      lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Predefined termination criterion of &gt; 10 patients without CR or PR was matched.
  </why_stopped>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Remission Rate</measure>
    <time_frame>end of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>Number of Participants With Treatment-Related Adverse Events as Assessed by WHO Toxicity Grading Scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Indolent Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab, Gemcitabine and Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Rituximab on day 0 or 1 of each 28-day cycle Drug: Gemcitabine on day 1 and 15 of each 28-day cycle Drug: Oxaliplatin on day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²) of each 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Therapy with Rituximab, Gemcitabine and Oxaliplatin</intervention_name>
    <description>Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min. day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day 29 for 4 cycles</description>
    <arm_group_label>Rituximab, Gemcitabine and Oxaliplatin</arm_group_label>
    <other_name>Rituximab = Mabthera, Rituxan</other_name>
    <other_name>Gemcitabine = Gemzar</other_name>
    <other_name>Oxaliplatin = Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Need for therapy in patients with relapsed/refractory patients

          -  Histological proven diagnosis of an indolent B-cell lymphoma according to the World
             Health Organization (WHO) classification belonging to one of the following entities:

               -  follicular lymphoma

               -  mantle cell lymphoma

               -  lymphoplasmacytic lymphoma

               -  nodal or splenic marginal zone lymphoma

               -  measurable disease

               -  lymphoma specific therapy in the last four weeks

               -  WHO performance grade 0, 1 or 2

        Exclusion Criteria

          -  Patients suitable for high dose therapy

          -  Transformation in high grade lymphoma

          -  Leukocytes &lt; 1,5/nl or platelets &lt; 100/nl (except due to lymphoma)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Hoffmann, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Low Grade Lymphoma Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.lymphome.de/Gruppen/GLSG/Protokolle/GO/index.jsp</url>
    <description>web site in german language</description>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <last_update_submitted>August 17, 2015</last_update_submitted>
  <last_update_submitted_qc>August 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>German Low Grade Lymphoma Study Group</investigator_affiliation>
    <investigator_full_name>Martin Hoffmann</investigator_full_name>
    <investigator_title>Dr. Martin Hoffmann, Klinikum Ludwigshafen</investigator_title>
  </responsible_party>
  <keyword>relapsed indolent lymphoma</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

